Cargando…

Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong

BACKGROUND: There are limited data on head-to-head comparative risk of stroke between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA). We compared risk of stroke with its subtypes and incident atrial fibrillation (AF) between them. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Lui, David Tak Wai, Tang, Eric Ho Man, Wu, Tingting, Au, Ivan Chi Ho, Lee, Chi Ho, Woo, Yu Cho, Tan, Kathryn Choon Beng, Wong, Carlos King Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960638/
https://www.ncbi.nlm.nih.gov/pubmed/36829226
http://dx.doi.org/10.1186/s12933-023-01772-0
_version_ 1784895560065482752
author Lui, David Tak Wai
Tang, Eric Ho Man
Wu, Tingting
Au, Ivan Chi Ho
Lee, Chi Ho
Woo, Yu Cho
Tan, Kathryn Choon Beng
Wong, Carlos King Ho
author_facet Lui, David Tak Wai
Tang, Eric Ho Man
Wu, Tingting
Au, Ivan Chi Ho
Lee, Chi Ho
Woo, Yu Cho
Tan, Kathryn Choon Beng
Wong, Carlos King Ho
author_sort Lui, David Tak Wai
collection PubMed
description BACKGROUND: There are limited data on head-to-head comparative risk of stroke between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA). We compared risk of stroke with its subtypes and incident atrial fibrillation (AF) between them. METHODS: A population-based, retrospective cohort of patients with type 2 diabetes between 2008 and 2020 were identified from the electronic health records of Hong Kong Hospital Authority. Patients who received SGLT2i or GLP-1RA were matched pairwise by propensity score. Risks of stroke and AF were evaluated by hazard ratios (HRs) from the Cox proportional hazard regression models. RESULTS: A total of 5840 patients (2920 SGLT2i users; 2920 GLP-1RA users) were included (mean age 55.5 years, 56.1% men, mean HbA1c 8.9% and duration of diabetes 13.7 years). Upon median follow-up of 17 months, there were 111 (1.9%) events of stroke (SGLT2i: 62, 2.1%; GLP-1RA: 49 1.7%). SGLT2i users had comparable risk of all stroke as GLP-1RA users (HR 1.46, 95% CI 0.99–2.17, p = 0.058). SGLT2i users had higher risk of ischemic stroke (HR 1.53, 95% CI 1.01–2.33, p = 0.044) but similar risk of hemorrhagic stroke compared to GLP-1RA users. Although SGLT2i was associated with lower risk of incident AF (HR 0.43, 95% CI 0.23–0.79, p = 0.006), risk of cardioembolic stroke was similar. CONCLUSIONS: Our real-world study demonstrated that GLP-1RA use was associated with lower risk of ischemic stroke, despite the association between SGLT2i use and lower risk of incident AF. There was no significant difference in hemorrhagic stroke risk. GLP-1RA may be the preferred agent for patients with type 2 diabetes at risk of ischemic stroke. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-023-01772-0.
format Online
Article
Text
id pubmed-9960638
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99606382023-02-26 Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong Lui, David Tak Wai Tang, Eric Ho Man Wu, Tingting Au, Ivan Chi Ho Lee, Chi Ho Woo, Yu Cho Tan, Kathryn Choon Beng Wong, Carlos King Ho Cardiovasc Diabetol Research BACKGROUND: There are limited data on head-to-head comparative risk of stroke between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA). We compared risk of stroke with its subtypes and incident atrial fibrillation (AF) between them. METHODS: A population-based, retrospective cohort of patients with type 2 diabetes between 2008 and 2020 were identified from the electronic health records of Hong Kong Hospital Authority. Patients who received SGLT2i or GLP-1RA were matched pairwise by propensity score. Risks of stroke and AF were evaluated by hazard ratios (HRs) from the Cox proportional hazard regression models. RESULTS: A total of 5840 patients (2920 SGLT2i users; 2920 GLP-1RA users) were included (mean age 55.5 years, 56.1% men, mean HbA1c 8.9% and duration of diabetes 13.7 years). Upon median follow-up of 17 months, there were 111 (1.9%) events of stroke (SGLT2i: 62, 2.1%; GLP-1RA: 49 1.7%). SGLT2i users had comparable risk of all stroke as GLP-1RA users (HR 1.46, 95% CI 0.99–2.17, p = 0.058). SGLT2i users had higher risk of ischemic stroke (HR 1.53, 95% CI 1.01–2.33, p = 0.044) but similar risk of hemorrhagic stroke compared to GLP-1RA users. Although SGLT2i was associated with lower risk of incident AF (HR 0.43, 95% CI 0.23–0.79, p = 0.006), risk of cardioembolic stroke was similar. CONCLUSIONS: Our real-world study demonstrated that GLP-1RA use was associated with lower risk of ischemic stroke, despite the association between SGLT2i use and lower risk of incident AF. There was no significant difference in hemorrhagic stroke risk. GLP-1RA may be the preferred agent for patients with type 2 diabetes at risk of ischemic stroke. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-023-01772-0. BioMed Central 2023-02-24 /pmc/articles/PMC9960638/ /pubmed/36829226 http://dx.doi.org/10.1186/s12933-023-01772-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Lui, David Tak Wai
Tang, Eric Ho Man
Wu, Tingting
Au, Ivan Chi Ho
Lee, Chi Ho
Woo, Yu Cho
Tan, Kathryn Choon Beng
Wong, Carlos King Ho
Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong
title Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong
title_full Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong
title_fullStr Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong
title_full_unstemmed Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong
title_short Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong
title_sort risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in hong kong
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960638/
https://www.ncbi.nlm.nih.gov/pubmed/36829226
http://dx.doi.org/10.1186/s12933-023-01772-0
work_keys_str_mv AT luidavidtakwai risksofstrokeitssubtypesandatrialfibrillationassociatedwithglucagonlikepeptide1receptoragonistsversussodiumglucosecotransporter2inhibitorsarealworldpopulationbasedcohortstudyinhongkong
AT tangerichoman risksofstrokeitssubtypesandatrialfibrillationassociatedwithglucagonlikepeptide1receptoragonistsversussodiumglucosecotransporter2inhibitorsarealworldpopulationbasedcohortstudyinhongkong
AT wutingting risksofstrokeitssubtypesandatrialfibrillationassociatedwithglucagonlikepeptide1receptoragonistsversussodiumglucosecotransporter2inhibitorsarealworldpopulationbasedcohortstudyinhongkong
AT auivanchiho risksofstrokeitssubtypesandatrialfibrillationassociatedwithglucagonlikepeptide1receptoragonistsversussodiumglucosecotransporter2inhibitorsarealworldpopulationbasedcohortstudyinhongkong
AT leechiho risksofstrokeitssubtypesandatrialfibrillationassociatedwithglucagonlikepeptide1receptoragonistsversussodiumglucosecotransporter2inhibitorsarealworldpopulationbasedcohortstudyinhongkong
AT wooyucho risksofstrokeitssubtypesandatrialfibrillationassociatedwithglucagonlikepeptide1receptoragonistsversussodiumglucosecotransporter2inhibitorsarealworldpopulationbasedcohortstudyinhongkong
AT tankathrynchoonbeng risksofstrokeitssubtypesandatrialfibrillationassociatedwithglucagonlikepeptide1receptoragonistsversussodiumglucosecotransporter2inhibitorsarealworldpopulationbasedcohortstudyinhongkong
AT wongcarloskingho risksofstrokeitssubtypesandatrialfibrillationassociatedwithglucagonlikepeptide1receptoragonistsversussodiumglucosecotransporter2inhibitorsarealworldpopulationbasedcohortstudyinhongkong